Robuta

Sponsor of the Day: Jerkmate
https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-4/ Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent... Jul 7, 2025 - TORONTO, May 12, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life... provides updateresearch studynerve agentrevivetherapeutics https://jaims.in/jaims/article/view/5796 A Prospective Pilot Study Evaluating the Efficacy and Safety of Jeevan Sanjeevini Kadha in... pilot studyprospectiveevaluatingefficacysafety https://www.einpresswire.com/article/675077467/stroke-survivors-and-healthy-volunteers-needed-to-participate-in-dallas-fort-worth-study-evaluating-wearable-device Stroke Survivors and Healthy Volunteers Needed to Participate in Dallas-Fort Worth Study Evaluating... Dec 14, 2023 - Alva Health, Inc., a medical device startup developing a wearable device to recognize patterns indicative of stroke, in collaboration with the Brain Injury dallas fort worthstroke survivorshealthy volunteersstudy evaluatingneeded https://medicine.yale.edu/cancer/trial/a-phase-1-study-of-bg-75098-alone-and-in-combo-with-other-agents/ A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics,... The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and open label studyphase1a1bevaluating